Altre lingue Annexon, Inc.

Azioni

ANNX

US03589W1027

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 23/04/2024			Variaz. 5gg	Var. 1 gen.
4,44 ^USD	-2,31%		-13,20%	-2,20%

01/04	ANNEXON, INC. : JPMorgan Chase conferma il rating Buy	ZM
27/03	ANNEXON, INC. : Wells Fargo Securities mantiene la raccomandazione Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

ANNEXON REPORTS INDUCEMENT GRANTS TO NEW EMPLOYEES UNDER NASDAQ LISTING RULE 5635(4)	17/04
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)	16/04
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference	03/04
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference	03/04
Annexon Q4 Loss Narrows	26/03
Annexon, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones	26/03
Annexon, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03
North American Morning Briefing : Stocks Struggle After New Records	22/03
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)	18/03
North American Morning Briefing : Inflation Worries Continue to Weigh on Mood	15/03
North American Morning Briefing : Stock Futures -2-	04/03
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference	27/02
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference	27/02
ANNEXON REPORTS INDUCEMENT GRANT TO NEW EMPLOYEE UNDER NASDAQ LISTING RULE 5635(4)	21/02
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach	21/02
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach	21/02
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)	20/02
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases	08/01
Annexon Insider Bought Shares Worth $1,008,000, According to a Recent SEC Filing	28/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Annexon, Inc.

Azioni

ANNX

US03589W1027

Altre lingue

Filtri